Maruti Suzuki India: Quotes, News

BSE 12630.95122.65 (-0.97%)

NSE 12631.00122 (-0.97%)

Jaiprakash Associates:

Sudarshan Sukhani, s2analytics.com advises traders to buy Jaiprakash Associates on dip.

Sukhani told CNBC-TV18, "Luckily for us Jaiprakash Associates and DLF have been in an uptrend even prior to this breakout and we have been talking about going and buying them and JP has been a favourite. JP is coming out of a bear market, it is already in a bull trend every dip, every breakout here is a buying opportunity."

BHEL:

Phani Sekhar of Angel Broking is of the view that one should exit BHEL.

Sekhar told CNBC-TV18, "My advice would be to get out of BHEL because if one looks at the current five year plans, power addition capacity of 108,000 megawatts, it is very unlikely that in the current scenario where land acquisition is a problem. You have problem with State Electricity Board (SEB) finances, coal availability. Very highly unlikely that it will cross more than 80,000 megawatt for the entire five year plan and even within that for the first three years, FY13 is the first year, it is unlikely that we will be logging in more than 15,000 megawatt every year. BHEL's capacity utilisation in that case will dip to under 50 percent, that will consequently lead to operating margins coming down to below 5 percent in very low single digits.

Maruti Suzuki:

ICICIdirect.com is bullish on Maruti Suzuki and has recommended buMaruti Suzuki , a leading automobile manufacturer in India enjoys a healthy bull run on the bourses from a long term horizon. The share price remains in secular uptrend as it continues to steer northwards in a rising peaks and troughs manner on the longer term scale. y rating on the stock with a target of Rs 1750 in its January 2, 2013 research report.

Dr Reddys Labs:

Emkay Gobal Financial Services is bullish on Dr Reddys Labs and has recommended buy rating on the stock with a target of Rs 2250 in its January 1, 2013 research report.

US business which is 50% of its formulation biz will grow by 19% CAGR over FY12-15 on back of niche launches like Toprol, Vidaza and 30 other new launches Expect 15% CAGR in Russia business over FY12-15E led by strong OTC portfolio and 9% CAGR in India under DPCO impact , however impact will be minimum across industry.

GoodReturns.in

DISCLAIMER: GoodReturns provides you with information covering shares, futures and options based on broker's reports as stated on various media. Investors are, however, warned that they should NOT take any buy or sell decision based on these views expressed in the article. Investors should consult their own financial and share advisors before taking purchase or sale decisions. GoodReturns does not take any responsibility for any losses incurred by investors who take their cues from the above article.